How were Talaris Therapeutics' earnings last quarter?

Talaris Therapeutics, Inc. (NASDAQ:TALS) announced its quarterly earnings data on Friday, November, 12th. The company reported ($0.32) EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.03.

How often does Talaris Therapeutics pay dividends? What is the dividend yield for Talaris Therapeutics?

Talaris Therapeutics declared a dividend on Thursday, October 19th. Shareholders of record on Monday, October 16th will be paid a dividend of $1.5118 per share on Friday, October 20th. The ex-dividend date of this dividend is Friday, October 20th. Read our dividend analysis for TALS .

When did Talaris Therapeutics IPO?

Talaris Therapeutics (TALS) raised $150 million in an initial public offering (IPO) on Friday, May 7th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Evercore ISI and Guggenheim Securities acted as the underwriters for the IPO.

NASDAQ:TALS

Talaris Therapeutics (TALS) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free TALS Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $15.13
▼
$16.01
50-Day Range: $12.36
▼
$28.36
52-Week Range: $0.89
▼
$27.95

Volume: 737,656 shs
Average Volume: 386,531 shs
Market Capitalization: $660.70 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Competitors Dividend Earnings Headlines Insider Trades Ownership Social Media

Get Talaris Therapeutics alerts:

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Talaris Therapeutics Stock (NASDAQ:TALS)

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts.

Ad Crypto 101 Media

SHOCKING Crypto Leak…

Claim your free seat by clicking here now.

TALS Stock News Headlines

February 25, 2024 | benzinga.com

Longitude Venture Partners III, L.P.'s Net Worth

November 1, 2023 | msn.com

Talaris Therapeutics (TALS) Price Target Increased by 562.50% to 135.15

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

October 19, 2023 | msn.com

Talaris Therapeutics goes ex-dividend tomorrow

October 18, 2023 | finanznachrichten.de

Talaris Therapeutics, Inc.: Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio

October 17, 2023 | msn.com

Talaris shareholders approve merger, 1-for-10 reverse stock split

October 17, 2023 | finance.yahoo.com

Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio

October 6, 2023 | marketwatch.com

Shares of Talaris Therapeutics Climb 5.2% on Special Dividend Tied to Merger

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

October 6, 2023 | finance.yahoo.com

Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio

October 4, 2023 | finance.yahoo.com

New York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris Therapeutics

September 12, 2023 | finance.yahoo.com

We're Keeping An Eye On Talaris Therapeutics' (NASDAQ:TALS) Cash Burn Rate

August 15, 2023 | markets.businessinsider.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AEL, DEN, TALS, QUOT

August 14, 2023 | finance.yahoo.com

ImmunoFree Inc. has Acquired Talaris Therapeutics, Inc.'s Tolerance Business

August 8, 2023 | markets.businessinsider.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NEX, TALS, QUOT, SURF

July 28, 2023 | benzinga.com

Moore Kuehn Encourages RETA, TALS, INPX, and DEN Investors to Contact Law Firm

July 27, 2023 | markets.businessinsider.com

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Talaris Therapeutics, Inc. (TALS)

July 18, 2023 | markets.businessinsider.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NETI, QUOT, TALS, CFMS

July 18, 2023 | msn.com

Talaris Therapeutics: Cashing Out Ahead Of Tourmaline Merger

July 6, 2023 | msn.com

Talaris Therapeutics (TALS) Price Target Increased by 66.67% to 12.75

June 27, 2023 | markets.businessinsider.com

IMPORTANT ALERT: Halper Sadeh LLC Investigates TALS, DICE, NEX, NETI

June 26, 2023 | businesswire.com

TALARIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Talaris Therapeutics, Inc. - TALS

June 23, 2023 | benzinga.com

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Talaris Therapeutics, Inc. Merger

June 23, 2023 | bizjournals.com

Talaris Therapeutics announces merger after layoffs

June 22, 2023 | bizjournals.com

NY biotech to go public by merging with Boston firm that laid off 95% of staff

June 22, 2023 | msn.com

Talaris jumps 29% on merger with Tourmaline Bio in all-stock deal

June 22, 2023 | markets.businessinsider.com

IMPORTANT ALERT: Halper Sadeh LLC Investigates TALS, SURF, NEX, CIR

See More Headlines

Receive TALS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Talaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/12/2021
Today: 4/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:TALS
CUSIP: N/A
CIK: 1827506
Web: talaristx.com
Phone: 502-398-9250
Fax: N/A
Employees: 84
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.79)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-73,890,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -39.93%
Return on Assets: -37.37%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 15.41
Quick Ratio: 15.41

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.33 per share
Price / Book: 3.57

Miscellaneous

Outstanding Shares: 42,764,000
Free Float: 35,708,000
Market Cap: $660.70 million
Optionable: Not Optionable
Beta: 2.18

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Ms. Mary Kay Fenton (Age 59)
Interim CEO, Pres, CFO & Treasurer
Comp: $598.98k
Dr. Suzanne T. Ildstad M.D. (Age 70)
Founder, Member of Scientific Advisory Board, Sr. Scientific Advisor & Director
Comp: $318.3k
Ms. Suzanne Tollerud
VP of Corp. Devel.

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

TALS Stock Analysis - Frequently Asked Questions

How were Talaris Therapeutics' earnings last quarter?: Talaris Therapeutics, Inc. (NASDAQ:TALS) announced its quarterly earnings data on Friday, November, 12th. The company reported ($0.32) EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.03.
How often does Talaris Therapeutics pay dividends? What is the dividend yield for Talaris Therapeutics?: Talaris Therapeutics declared a dividend on Thursday, October 19th. Shareholders of record on Monday, October 16th will be paid a dividend of $1.5118 per share on Friday, October 20th. The ex-dividend date of this dividend is Friday, October 20th.
Read our dividend analysis for TALS.
When did Talaris Therapeutics IPO?: Talaris Therapeutics (TALS) raised $150 million in an initial public offering (IPO) on Friday, May 7th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Evercore ISI and Guggenheim Securities acted as the underwriters for the IPO.

This page (NASDAQ:TALS) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Talaris Therapeutics (TALS) Stock Price, News & Analysis

About Talaris Therapeutics Stock (NASDAQ:TALS)

TALS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

TALS Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info